For all press and media enquiries please contact mediarelations@chiesi.com
At the 2024 European Respiratory Society Congress (ERS), Chiesi Group will convene two symposia to highlight the importance of patient centricity in managing asthma and COPD Chiesi Group will present the value for patients in using innovative decentralized elements in clinical trial design, with…
Chiesi Group announces a major step in the development of carbon minimal inhalers with the initiation of a new phase III long-term safety trial. The trial comes after the completion of two short-term clinical safety studies with the new low global warming potential propellant and three clinical…
FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB) FILSUVEZ was well tolerated and met the primary endpoint with statistical significance, with 41.3% of patients achieving first…
- European Commission decision anticipated in beginning of May 2023 - PARMA, Italy and BOSTON and CARMIEL, Israel, February 24 th, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases,…
Company also presents insights from the SPARKLE registry in alpha-mannosidosis that highlight a delay in diagnosis, identify the most frequent genetic MAN2B1 variant in enrolled participants, and report on real-world clinical profiles. BOSTON, February 24, 2023 – Chiesi Global Rare Diseases, a…
First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients; Ultra-rare progressive disease presents with wide range of symptoms. BOSTON, February 20, 2023 – Chiesi Global Rare Diseases, a business…
Chiesi Group announces positive results of pharmacokinetic (PK) studies completed in May 2022 on a leading inhaler in development for the treatment of asthma and COPD, formulated with a new low global warming potential propellant. Promising results with the new formulation show a similar profile…
New investment will progress potential treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure and remodeling in the blood vessels that supply the lungs and can lead to heart failure. Current approved medications mainly address the symptoms of this rare…
PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta. Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102. BLA resubmission planned for the second half of 2022. CARMIEL, Israel and…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
